Search results
Author(s):
Wolfgang Koenig
,
Natalie Khuseyinova
Added:
3 years ago
Atherosclerosis is characterized by a non-specific local inflammatory process accompanied by a systemic response. A number of prospective studies in initially healthy subjects and in patients with manifest atherosclerosis have now convincingly demonstrated a strong and independent association between even slightly elevated concentrations of various systemic markers of inflammation and a number of…
View more
Author(s):
Erik B Friedrich
,
Michael Böhm
Added:
3 years ago
Chronic heart failure (CHF) is a major public health problem in industrialized societies, with an incidence approaching 10 per 1,000 population after age 65 and an age-dependent prevalence of less than 1% between ages 45 and 55, 2-5% between ages 65 and 75, and approximately 10% for patients aged 80 years or more.1-3 Thus, HF is primarily a condition of the elderly, and approximately 80% of…
View more
Author(s):
William T Abraham
Added:
3 years ago
Hyponatremia is the most common electrolytic abnormality in clinical practice and has a reported incidence of 15–30% in adults.1,2 It is particularly common in heart failure: the Organized Program to Initiate Life Saving Treatment in Patients Hospitalized for Heart Failure (OPTIMIZE-HF) registry recorded that 25.3% of 47,647 heart failure patients had hyponatremia on admission.3 In this registry,…
View more
Author(s):
Sophia Zoungas
,
John Chalmers
,
Anushka Patel
Added:
3 years ago
Summary of the ADVANCE Trial Findings
The ADVANCE trial was a factorial, randomised study of 11,140 individuals with type 2 diabetes from over 200 collaborating centres in 20 countries from Asia, Australasia, Europe and North America. Participants with either a history of macrovascular or microvascular disease or at least one major risk factor for cardiovascular disease and any initial level of…
View more
Author(s):
G Michael Felker
,
Christopher B Granger
Added:
3 years ago
Chronic heart failure is common, disabling and deadly. It affects approximately five million people in the US and accounts for over one million hospitalizations annually.1 Despite continued improvements in heart failure therapy, mortality over five years is approximately 50%.2 This article summarizes significant recent developments in pharmacologic and device therapy for heart failure.
…
View more
Author(s):
Mirvat Alasnag
,
Waqar Ahmed
,
Ibrahim Al-Nasser
,
et al
Added:
2 years ago
Acute Heart Failure Syndromes
Author(s):
Mihai Gheorghiade
Added:
3 years ago
Article
Single-Ventricle Physiology
Author(s):
Lydia Taranto
,
Tabitha Moe
Added:
3 years ago
Article
Transvenous Phrenic Nerve Stimulation - A Novel Therapy for Central Sleep Apnea in Heart Failure
Author(s):
Sitaramesh Emani
,
William T Abraham
Added:
3 years ago
Article
Author(s):
Debbie L Cohen
,
Raymond R Townsend
Added:
3 years ago
Chronic kidney disease (CKD) is increasingly prevalent, with an estimated 26 million adults with CKD in the US.1 Hypertension is the most common comorbidity in chronic kidney disease. At least 85% of patients with stage 3 CKD or greater have hypertension, making parenchymal kidney disease the most common ‘secondary’ form of hypertension. Treatment of hypertension can often be challenging, as…
View more